Zika virus (ZIKV) infection has been recognized since 1947, but just recently it became a worldwide major public health problem. The most common features of ZIKV infection are fever, cutaneous rash, arthralgia, and conjunctivitis but most affected patients with the clinical disease present with only mild symptoms. However, severe neurologic complications have been described:
Faced with this emerging scenario, governments and public health authorities are establishing strategies to control ZIKV infection and limit its potential complications. To increase the awareness of this health problem, the World Health Organisation (WHO) has recently made available an app, "WHO Zika App", which provides for health care workers, the latest information on ZIKV (http://www.who.int/risk-communication/zika-virus/app/en/).
Epidemiology of ZIKV
ZIKV was first isolated from a sentinel rhesus monkey placed in the Ugandan Zika Forest in 1947. A second isolation from the mosquito Aedes africanus followed at the same site in 1948. Since then, sporadic ZIKV isolations have been made from humans and a variety of mosquito species both in Africa and Asia, supported by seroprevalence studies in humans and animals (Haddow et al., 2012) . It is possible that ZIKV may have undergone recombination in nature and, after emerging in Uganda, it spread to West Africa and Asia, without any clear preference for any host or vector species (Faye et al., 2014 Given the worldwide spread of chikungunya and dengue, associated with urbanization and globalization, there is a potential risk of outbreaks of ZIKV infection in urban settings in any part of the world where the mosquito vectors are present or become established in future. Figure 1 highlights the countries affected by ZIKV and the year of the first described case in each place.
Modes of transmission of ZIKV
The ZIKV natural transmission cycle in urban and suburban environments is human-mosquito-human, involving mosquitoes of especially Aedes species.
Aedes aegypti and Aedes albopictus are responsible for the large majority of ZIKV outbreaks investigated.
According to the latest WHO situation report (11 May 2016) , person-to-person transmission of ZIKV has been documented in 9 countries, probably via a sexual route. The perinatal transmission has also been described, and the potential for transfusion-transmitted infection exists . 
Clinical and laboratory features of ZIKV disease
ZIKV infection is believed to be asymptomatic or mildly symptomatic in most cases. The incubation period ranges from 2 to 7 days. Symptoms can last for up to a week, with a clinical presentation similar to that of other arbovirus infections such as chikungunya and dengue. The most common signs and symptoms of ZIKV infection are rash, self-limiting acute fever, arthralgia, myalgia, headache, and conjunctivitis. The rash is most often maculopapular and pruritic. Table 1 ) and the Bredford Hill Criteria, concluded that current evidence is sufficient to establish ZIKV as a teratogen (Rasmussen et al. 2016 ).
Guillain-Barre syndrome (GBS)
GBS is an acute paralytic peripheral neuropathy characterized by nerve 
Prevention of ZIKV transmission
Like many vector-borne diseases, the absence of vaccines and specific treatment against ZIKV means prevention and control are largely based on vector control and standard control of cross-infection methods. Prevention against mosquito bites (particularly daytime bites) is best offered by leaving skin as little exposed and covered with mosquito repellents. Icaridin provides up to 10 hours of protection and has been the first option for adults and pregnant women. Repellents are not recommended for use on babies younger than 2 months old; oil of lemon eucalyptus or para-menthane-diol repellents are not recommended for children younger than 3 years old.
Other prevention measures, include the elimination of mosquito breeding sites, limiting travel to affected areas, avoiding unprotected sex and taking precautions to avoid the risk of transfusion-transmission of ZIKV, for example by deferring potential blood donors returning from affected areas (http://www.cdc.gov/mmwr/volumes/65/wr/mm6512e3.htm, http://www.cdc.gov/zika/transmission/blood-transfusion.html).
The Butantan Institute in San Paulo, Brazil along with two other laboratories connected to the Brazil health ministry, and the U.S. government is also working on vaccines. One approach is a DNA-based vaccine involving a newer technique that injects a piece of the viral DNA rather than a protein fragment of the virus to stimulate the immune system. The other is known as a "live attenuated" approach, which uses a version of attenuated live ZIKV.
Management of ZIKV infection
Zika virus infection typically results in a relatively mild and self-limiting clinical illness. With the lack of specific treatment, infected individuals should be given adequate rest and hydration, and fever reduction using paracetamol rather than aspirin and non-steroidal anti-inflammatory drugs (NSAIDs Findings are similar to those seen after prenatal infection with some other viral teratogens (eg rubella virus, cytomegalovirus). Animal models have shown that ZIKV is neurotropic, which supports biologic plausibility. Evidence that ZIKV infects neural progenitor cells and produces cell death and abnormal growth, along with evidence of ZIKV in brains of foetuses and infants with microcephaly, on the basis of immunohistochemical staining and identification of ZIKV RNA and live virus, provides biologic plausibility.
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Proof in an experimental system that the agent acts in an unaltered state
The criterion applies to a medication or chemical exposure, not to infectious agents.
NA * Criteria 1,2 and 3 or criteria 1, 3 and 4 are considered to be essential, whereas criteria 5,6 and 7 are helpful but not essential. Partial evidence is insufficient to meet a criterion. ZIKV -Zika virus; NA -not applicable Figure 1 . The ZIKV virus, which is commonly found in parts of Africa and South East Asia spread to Latin America via French Polynesia. Last year more than 1.5 million people in South America became infected, before the virus spread to the Caribbean, Mexico and Texas towards the end of 2015 (Published: 13:53  GMT, 5 February 2016, Daily Mail) 
